Key Highlights

  • 8.17% is the indicated pre-market decline for GRI Bio, Inc. (NASDAQ:GRI) on November 18, 2026, taking the price to USD 1.24 from a calculated prior close of USD 1.35, a calculated move of negative USD 0.11.
  • 9.5 million USD was cash at September 30, 2026, up 15% from December 31, 2025, which management expects to fund planned preliminary operations through the second quarter of 2027, after USD 6.6 million of operating cash use.
  • 339% was the rise in shares outstanding to about 2.19 million at September 30, 2026 from 497,693 at December 31, 2025, as roughly 1.69 million at-the-market shares raised USD 8.2 million gross.
  • 99 mL was the exploratory placebo-adjusted improvement in forced vital capacity in the 35-patient, 12-week Phase 2a trial of GRI-0621, rising to 139 mL in the standard-of-care subset, and not proof of efficacy.

What Moved GRI Bio, Inc. (NASDAQ:GRI) in Pre-Market Trading on November 18, 2026 (-USD 0.11, -8.17%)

The indicated pre-market price for GRI Bio, Inc. (NASDAQ:GRI) is USD 1.24 on November 18, 2026, a pre-market move of -8.17%. The calculated prior close, meaning the November 17, 2026 regular-session close, is USD 1.35 (USD 1.24 divided by 0.9183), and the calculated USD move is negative USD 0.11. Multiplying about 2.19 million shares outstanding at September 30, 2026 by the indicated price gives a calculated Market Value of roughly USD 2.72 million. Pre-market Volume figures were not found.

The Rationale: No Fresh Catalyst After Third Quarter Update for GRI Bio, Inc. (NASDAQ:GRI)

No company announcement dated November 18, 2026 was identified in published coverage. The latest company update found is the third quarter report published around November 13, 2026, covering the period to September 30, 2026. After a Type C meeting request, the company received written FDA feedback and plans another meeting to discuss a proposed Phase 2b or adaptive Phase 2b/3 design; the feedback and budget were not disclosed. As general context, clinical-stage micro-caps often drift lower after updates.

Valuation, Liquidity and Risks for GRI Bio, Inc. (NASDAQ:GRI)

The company reports substantial doubt about its ability to continue as a going concern. Cash of USD 9.5 million at September 30, 2026 compares with USD 6.6 million of operating cash use over nine months, and the company expects the balance to support planned preliminary operations through the second quarter of 2027. Dilution is a material risk: shares outstanding rose to about 2.19 million from 497,693, about 517,000 warrants were outstanding, roughly 24% of September 30 shares. The company says its market value of listed securities is below USD 5 million, and a new Nasdaq listing requirement, stayed pending review, could lead to suspension and delisting proceedings if it takes effect. A calculated market value near USD 2.72 million places the shares in the nano-cap range, where Volatility is elevated.

Where Things Stand

GRI Bio, Inc. (NASDAQ:GRI) is indicated down 8.17% in pre-market trading on November 18, 2026, at USD 1.24, a calculated USD 0.11 below a calculated prior close of USD 1.35. No specific catalyst was identified in published coverage. Cash was USD 9.5 million at September 30, 2026, while shares outstanding rose 339% to about 2.19 million and a calculated market value is near USD 2.72 million. The lead candidate GRI-0621 showed an exploratory 99 mL placebo-adjusted forced vital capacity gain in a 35-patient trial, and a Phase 2b or adaptive Phase 2b/3 design is under discussion with the FDA. Pre-market moves can reverse at the open, and this article is not Investment advice.